Annexon Q2 net loss $35.2M; GA visual function data; GBS enrollment completion in H2 2023

Annexon, Inc.

2023-Q2 EPS reported -$0.99

ANX007 (GA) ARCHER Phase 2 data showed dose-dependent preservation of visual function; regulatory engagement planned.
Phase 3 pivotal trial of ANX005 in GBS enrollment to complete in H2 2023; topline results expected H1 2024.
Appointed Jamie Dananberg, M.D., as CMO; brings >20 years of drug development experience.
Cash and equivalents $192.9M as of June 30, providing runway into 2025. Q2 net loss $35.2M ($0.47 per share).
Upcoming catalysts: ANX1502 Phase 1a data (H2 2023), ANX009 LN Phase 1b data, ALS Phase 2a data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annexon, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $35.2 million or $0.47 per share for the quarter ended June 30, 2023, EPS $0.47 per share.

Period: the second quarter ended June 30, 2023
Net income: Net loss was $35.2 million or $0.47 per share for the quarter ended June 30, 2023
EPS: $0.47 per share
Result: reported results

Exact text from the filing

Annexon, Inc. (the “Company”) announced certain financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.